ArticlePloS one2021
Cholesterol efflux capacity and its association with prevalent metabolic syndrome in a multi-ethnic population (Dallas Heart Study).
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Insulin Resistance is Associated With Skin Microvascular Dysfunction and Reduced Circulating Endothelial Progenitor Cells in Hypertensive Patients.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- High Density Lipoprotein Assessment Revisited: A Review of Foundational Understanding and Recent Developments in Function, Particle Size, and Cardiometabolic Impact.Current atherosclerosis reports · 2026Review
- HDL Functionality in Metabolic Syndrome: Insights From Cholesterol Efflux Capacity and NMR Spectroscopy.Health science reports · 2025Article
- High-Density Lipoprotein Lipid and Protein Cargo and Cholesterol Efflux Capacity Before and After Bariatric Surgery.Arteriosclerosis, thrombosis, and vascular biology · 2025Observational
- Dysfunctional HDL Diagnostic Metrics for Cardiovascular Disease Risk Stratification: Are we Ready to Implement in Clinics?Journal of cardiovascular translational research · 2025Review
- Ethnic Disparities in the Risk Factors, Morbidity, and Mortality of Cardiovascular Disease in People With Diabetes.Journal of the Endocrine Society · 2024Review
- HDL-C and apolipoprotein A-I are independently associated with skeletal muscle mitochondrial function in healthy humans.American journal of physiology. Heart and circulatory physiology · 2024Article
- Oxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk.Biomedicines · 2023Review
- Metabolomic Profiling of Cholesterol Efflux Capacity in a Multiethnic Population: Insights From MESA.Arteriosclerosis, thrombosis, and vascular biology · 2023Article
- Prevalence of Antiphospholipid Antibodies and Association With Incident Cardiovascular Events.JAMA network open · 2023Article
- The Association between the Atherogenic Index of Plasma and Cardiometabolic Risk Factors: A Review.Healthcare (Basel, Switzerland) · 2023Review
- The Importance of HDL-Cholesterol and Fat-Free Percentage as Protective Markers in Risk Factor Hierarchy for Patients with Metabolic Syndrome.Metabolites · 2022Article
- Changes in HDL cholesterol, particles, and function associate with pediatric COVID-19 severity.Frontiers in cardiovascular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Metabolic syndrome (MetS) is characterized by adiposity and atherogenic dyslipidemia consisting of elevated triglyceride and decreased high density lipoprotein cholesterol (HDL-C) levels however, cholesterol concentration alone does not reflect HDL functionality. Cholesterol efflux capacity (CEC) captures a key anti-atherosclerotic function of HDL; studies linking CEC to MetS have yielded inconsistent findings and lacked racial/ethnic diversity. The aim of this study was to evaluate the association between CEC and MetS in a large multi-ethnic population utilizing two different CEC assays interrogating overlapping but distinct reverse cholesterol transport pathways. A cross-sectional study was performed using the Dallas Heart Study cohort and cholesterol efflux was measured with radiolabeled and fluorescent cholesterol assays. The relationship between CEC and MetS was assessed using multivariable regression analyses. A total of 2241 participants were included (mean age was 50 years; 38% men and 53% Blacks). CEC was independently and inversely associated with MetS irrespective of efflux assay (CEC-radiolabeled, adjusted OR 0·71 [95% CI 0·65-0·80]. CEC-fluorescent, adjusted OR 0·85 [95% CI 0·77-0·94]). Both CEC measures were inversely associated with waist circumference and directly associated with HDL-C but not with other MetS components. There was an interaction by sex but not by race such that the inverse associations between CEC and MetS were somewhat attenuated in men (OR 0·86, 95%CI 0·74-1·01). In this large multi-ethnic cohort, impaired CEC is linked to MetS irrespective of efflux assay and race/ethnicity but less so among men. Future studies are needed to assess whether CEC mediates the atherosclerotic cardiovascular disease risk of MetS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.